Funded Biotechnology Startups in Rockville
Rockville, Maryland has produced a consistent stream of biotechnology funding rounds from early 2023 through mid-2025.
Rockville, Maryland has produced a consistent stream of biotechnology funding rounds from early 2023 through mid-2025. Among the ten most recent rounds on record, disclosed amounts range from $2M (CellPhire, October 2023) to $150M — a figure reached twice, by Supernus Pharmaceuticals in February 2023 and REGENXBIO in May 2025. The segment spans pharmaceutical developers, gene therapy platforms, cell and tissue engineering, and antimicrobial diagnostics, with AgNovos Bioscience ($32M, June 2023) and TissueGene ($30M, May 2023) filling the mid-range.
Round-type disclosure is limited across this cohort: nine of the ten rounds are classified as Series Unknown or carry no stage label, with American Gene Technologies International's Series F (September 2023, undisclosed amount) the only named stage. That pattern is characteristic of later-stage private placements and non-dilutive instruments common in the Maryland biotech corridor.
Most recent rounds
10 shownRelated listings
Frequently asked
What are the largest disclosed rounds among recently funded Rockville biotech companies?
REGENXBIO and Supernus Pharmaceuticals both raised $150M, the former in May 2025 and the latter in February 2023, making them the largest disclosed rounds in this set. AgNovos Bioscience ($32M, June 2023) and TissueGene ($30M, May 2023) are the next largest.
Which Rockville biotech companies closed rounds most recently?
Shuttle Pharmaceuticals closed a $4M round on June 20, 2025, followed by REGENXBIO's $150M round on May 19, 2025 — the two most recent entries in this dataset.
How transparent are round types for Rockville biotech funding activity?
Nine of the ten rounds are labeled Series Unknown or carry no stage designation at all (OpGen, March 2024). American Gene Technologies International is the only company with a named round type — a Series F closed in September 2023, with the amount undisclosed.
What sub-sectors are represented among recently funded Rockville biotech companies?
The dataset spans pharmaceutical developers (Shuttle Pharmaceuticals, CASI Pharmaceuticals, Supernus Pharmaceuticals), gene therapy platforms (REGENXBIO, American Gene Technologies International), cell and tissue engineering (CellPhire, TissueGene), neuroscience (NeuroCytonix), bone bioscience (AgNovos Bioscience), and antimicrobial diagnostics (OpGen).
What does the deal size distribution look like for these rounds?
Disclosed amounts range from $2M (CellPhire, October 2023) to $150M. Excluding the two $150M rounds, the remaining seven disclosed amounts — ranging from $2M to $32M — average roughly $12.9M, suggesting a cluster of mid-stage raises alongside a few larger outliers.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.